These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 5638968)

  • 1. [New information on obliterative disease of the peripheral vessels and its treatment].
    Masek O
    Vnitr Lek; 1968 Mar; 14(3):301-3. PubMed ID: 5638968
    [No Abstract]   [Full Text] [Related]  

  • 2. The significance of vasodilator therapy in obliterative arterial disease.
    Thulesius O
    Scand J Clin Lab Invest Suppl; 1967; 99():222-4. PubMed ID: 6056925
    [No Abstract]   [Full Text] [Related]  

  • 3. [On the treatment of "intermittent claudication" in chronic peripheral obliterating arteriopathies of the lower extremities caused by arteriosclerosis and Buerger's disease].
    Seghezzi R; Pedroni G; Borri P
    Chir Ital; 1967; 19():Suppl 2:222+. PubMed ID: 5190600
    [No Abstract]   [Full Text] [Related]  

  • 4. [Phonoangiographic demonstration of the effect of various vasodilators on patients with peripheral obliterans arteriosclerosis].
    Meciani L; Tealdi D; Santa A; Ricci G
    Minerva Cardioangiol; 1969 Nov; 17(11):942-7. PubMed ID: 5404822
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current news in the pharmacological and surgical treatment of chronic, peripheral, obliterating arterial diseases of the lower limbs].
    Argenteri A; Bagliani A; Borri P; Ugolini U
    Clin Ter; 1974 Aug; 70(3):281-91. PubMed ID: 4423739
    [No Abstract]   [Full Text] [Related]  

  • 6. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
    Shimamoto T; Atsumi T
    Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
    [No Abstract]   [Full Text] [Related]  

  • 7. Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid.
    Ost CR; Sténson S
    Scand J Clin Lab Invest Suppl; 1967; 99():241-5. PubMed ID: 6056927
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of surheme on improved blood flow in limbs].
    Wesolowski J; Hubl S; Godziemba-Maliszewska E
    Wiad Lek; 1972 Jul; 25(14):1297-300. PubMed ID: 5054661
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic properties of xanthine nicotinate in the treatment of obliterating arteriopathies].
    Tardito E; Azzolini A; De Cristofaro A; Papacharalambus D
    Minerva Cardioangiol; 1972; 20(7):369-89. PubMed ID: 5050745
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical trial of a long-acting vasodilator agent in chronic peripheral obliterating arteriopathy of a sclerotic nature].
    Gemma GB; Ghezzi P; Cavaliere P
    Minerva Cardioangiol; 1969 May; 17(5):324-32. PubMed ID: 5785730
    [No Abstract]   [Full Text] [Related]  

  • 11. [Are vasodilators indicated in the treatment of obliterative arteriopathy of the lower limbs?].
    Cuypers Y; Baudinet V; Collignon P; Joris H; Kulbertus H; Rutten F
    Rev Med Liege; 1966 Apr; 21(8):185-8. PubMed ID: 5932052
    [No Abstract]   [Full Text] [Related]  

  • 12. [Studies on the behavior of integrated capillary pressure impulses in arterial occlusion disease following intra-arterial drug-induced vasodilatation].
    Bartusch M; Mörl H; Preuss EG; Seige K
    Z Kreislaufforsch; 1971 May; 60(5):440-6. PubMed ID: 5557742
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of prostaglandin E1 in chronic obliterative diseases of peripheral arteries].
    Zhang GS
    Zhonghua Wai Ke Za Zhi; 1988 Sep; 26(9):541-2, 573. PubMed ID: 3243146
    [No Abstract]   [Full Text] [Related]  

  • 14. [Surheme in chronic obliterative arteriopathies of the lower limbs].
    Desruelles J; Waucampt JJ
    Lille Med; 1971 Jan; 16():Suppl 1:224-9. PubMed ID: 5162043
    [No Abstract]   [Full Text] [Related]  

  • 15. [Mydocalm administered in electrophoresis].
    Chmielewski F
    Pol Tyg Lek; 1971 Jul; 26(30):1170-2. PubMed ID: 5092988
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclospasmol in the treatment of peripheral vascular disease.
    SPENCER AM
    J Am Podiatry Assoc; 1963 Apr; 53():261-4. PubMed ID: 13990012
    [No Abstract]   [Full Text] [Related]  

  • 17. [Further trials of a long-acting vasodilator agent in 397 patients with cronic peripheral obliterating arteriopathy of a sclerotic nature].
    Ghezzi P; Cavaliere P; Berti Riboli E
    Minerva Cardioangiol; 1969 May; 17(5):333-6. PubMed ID: 5785731
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of the efficacy of vasodilator drugs in peripheral vascular disease through a study of skeletal muscle metabolism using 31P nuclear magnetic resonance (NMR) spectroscopy.
    Wahl D; Simon JP; Escanye JM; Jouanny P; Robin B; Walker P; Paille F; Schmidt C; Robert J; Schmitt J
    Therapie; 1992; 47(2):125-6. PubMed ID: 1412138
    [No Abstract]   [Full Text] [Related]  

  • 19. [Arterial occlusions in the extremities].
    Dembowski U
    Munch Med Wochenschr; 1965 Jun; 107(25):1242-6. PubMed ID: 5896972
    [No Abstract]   [Full Text] [Related]  

  • 20. [Test of active vasodilatation in the evaluation of peripheral regional circulation in sclerotic and diabetic arteriopathies].
    Dughera L; Macchioni P; Di Leo M; Nosenzo C
    Minerva Cardioangiol; 1972 Sep; 20(9):484-96. PubMed ID: 5071470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.